Trial Review

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06981299




Registration number
NCT06981299
Ethics application status
Date submitted
6/05/2025
Date registered
20/05/2025
Date last updated
20/05/2025

Titles & IDs
Public title
A Phase 1 Study of PROT-001.
Scientific title
A Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled 3-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PROT-001 in Healthy Adult Participants
Secondary ID [1] 0 0
PRO-1A-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PROT-001

Placebo comparator: SIngle ascending dose - Part 1 is a randomized, double-blind, placebo-controlled study to evaluate single ascending doses of PROT-001 in healthy adult participants. Up to 7 sequential cohorts (including 6 planned and 1 optional dose level) of approximately 8 participants each (6 receiving PROT-001 and 2 receiving placebo), will be initiated. The planned dose levels of PROT-001 are tentative, with the first 2 dose levels planned at 15 mg and 75 mg. Subsequent cohorts will have dose levels increased by no more than 3-fold of the previous evaluated dose with the maximum dose not exceeding a single dose of 1800 mg during Part 1 of the study.

Placebo comparator: Multiple ascending dose - Part 2 is a randomized, double-blind, placebo-controlled study to evaluate multiple ascending doses of PROT-001 in healthy adult participants. Up to 3 sequential cohorts of approximately 8 participants each (6 receiving PROT-001 and 2 receiving placebo), will be enrolled. Tentative doses between 600 and 1800 mg administered twice daily (BID) for 14 days will be explored, with a maximum dose not exceeding 3600 mg/day. The exact multiple dosing frequency (i.e., BID or once daily \[QD\]) will be determined based on the estimated half-life, PD, and safety data following the single doses evaluated in Part 1. The maximum dose for the first MAD cohort will be the BID dosing of the highest SAD dose deemed to be safe and well tolerated by the SRC.

Other: Food-effect - The Food-Effect arm is a randomized, open-label, 2-sequence, 2-period crossover, single-dose study to evaluate the effect of food on the PK of PROT-001 in 12 healthy adult participants. The proposed dose level will be a dose of PROT-001 that is deemed to be safe and well tolerated following single-dose administration, as determined following SRC review.

Other: Age-effect - The Age-Effect arm is an open-label, non-randomized, single-dose study to evaluate the effect of age on the PK of PROT-001 in healthy elderly participants (\>65 to 75 years of age). The proposed dose level will be a dose of PROT-001 that is deemed to be safe and well tolerated following single-dose administration, as determined following SRC review.


Treatment: Drugs: PROT-001
Orally bioavailable small molecule kinetic stabilizer of lambda light chains (?LCs).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety Outcome Measures (Adverse Events)
Timepoint [1] 0 0
From enrollment through 6 weeks for SAD participants, 7 weeks for MAD participants, and 7 weeks for Food Effect and Age Effect participants.
Primary outcome [2] 0 0
Safety outcome measures (Vital signs: Systolic Blood Pressure)
Timepoint [2] 0 0
From enrollment through 6 weeks for SAD participants, 7 weeks for MAD participants, and 7 weeks for Food Effect and Age Effect participants.
Primary outcome [3] 0 0
Safety outcome measures (Vital signs: Heart Rate)
Timepoint [3] 0 0
From enrollment through 6 weeks for SAD participants, 7 weeks for MAD participants, and 7 weeks for Food Effect and Age Effect participants.
Primary outcome [4] 0 0
Safety outcome measures (Vital signs: Respiratory Rate)
Timepoint [4] 0 0
From enrollment through 6 weeks for SAD participants, 7 weeks for MAD participants, and 7 weeks for Food Effect and Age Effect participants.
Primary outcome [5] 0 0
Safety outcome measures (Vital signs: Temperature)
Timepoint [5] 0 0
From enrollment through 6 weeks for SAD participants, 7 weeks for MAD participants, and 7 weeks for Food Effect and Age Effect participants.
Primary outcome [6] 0 0
Safety outcome measures (ECG QTCF Interval)
Timepoint [6] 0 0
From enrollment through 6 weeks for SAD participants, 7 weeks for MAD participants, and 7 weeks for Food Effect and Age Effect participants.
Primary outcome [7] 0 0
Safety outcome measures (Clinical Laboratory Parameters)
Timepoint [7] 0 0
From enrollment through 6 weeks for SAD participants, 7 weeks for MAD participants, and 7 weeks for Food Effect and Age Effect participants.
Primary outcome [8] 0 0
Safety Outcome Measures (Physical Exam)
Timepoint [8] 0 0
From enrollment through 6 weeks for SAD participants, 7 weeks for MAD participants, and 7 weeks for Food Effect and Age Effect participants.
Secondary outcome [1] 0 0
Pharmacokinetics Outcome Measures (Cmax)
Timepoint [1] 0 0
Day 1 for the SAD, Food Effect and Age Effect parts and Days 1 and 14 for the multiple dosing parts.
Secondary outcome [2] 0 0
Pharmacokinetics Outcome Measures (Tmax)
Timepoint [2] 0 0
Day 1 for the SAD, Food Effect and Age Effect parts and Days 1 and 14 for the multiple dosing parts.
Secondary outcome [3] 0 0
Pharmacokinetics Outcome Measures (half-life (t1/2))
Timepoint [3] 0 0
Day 1 for the SAD, Food Effect and Age Effect parts and Days 1 and 14 for the multiple dosing parts.
Secondary outcome [4] 0 0
Pharmacokinetics Outcome Measures (AUC0-t and AUC0-inf)
Timepoint [4] 0 0
Day 1 for the SAD, Food Effect and Age Effect parts and Days 1 and 14 for the multiple dosing parts.
Secondary outcome [5] 0 0
Pharmacokinetics Outcome Measures (Total Plasma Clearance (CL))
Timepoint [5] 0 0
Day 1 for the SAD, Food Effect and Age Effect parts and Days 1 and 14 for the multiple dosing parts.
Secondary outcome [6] 0 0
Pharmacokinetics Outcome Measures (Volume of Distribution (Vd))
Timepoint [6] 0 0
Day 1 for the SAD, Food Effect and Age Effect parts and Days 1 and 14 for the multiple dosing parts.
Secondary outcome [7] 0 0
Pharmacodynamics Outcome Measures (Light Chain (LC) Stabilization)
Timepoint [7] 0 0
From enrollment through Day 3 for SAD participants, through day 16 for MAD participants, through Day 3 for Age Effect participants.

Eligibility
Key inclusion criteria
1. Capable of providing written, signed, and dated participant informed consent prior to any study-related procedures, as described in Section 10.1.4.
2. For all study parts except Part 3 (Age-Effect study), participants must be between 18 and 65 years of age (inclusive) at the time of Screening (signing the ICF). For Part 3 (Age-Effect study) only, participants must be >65 to 75 years of age at the time of Screening.
3. Has a body mass index (BMI) of 18 to 32 kg/m2 (inclusive) and a body weight of =50 kg.
4. Is judged by the Investigator to be generally healthy, as determined by a medical history without major pathology, and no clinically significant findings based on physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory results obtained at Screening and on days of admission to the study site (Day -1 and Day 14, as appropriate).
5. For all study parts except Part 3 (Age-Effect study), estimated glomerular filtration rate (eGFR) must be >90 mL/min/1.73 m2 at Screening; for Part 3 (Age-Effect study), eGFR must be =60 mL/min/1.73 m2 (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation [2021]).
6. Has a resting (at least 5 minutes) pulse of 40 to 100 beats per minute and systolic and diastolic blood pressure (BP) of 90-140/40-90 mmHg.
7. Participants assigned female at birth are eligible to participate if they are not pregnant, not breastfeeding, and at least ONE of the following conditions applies:

* Are a participant of nonchildbearing potential:
* Surgically sterile (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or
* Are postmenopausal (amenorrhea for =12 months without an alternative medical cause AND a follicle-stimulating hormone [FSH] level >40 IU/L), or
* Is a woman of childbearing potential (WOCBP) and agree to have their partner use a condom, and, if their partner is not vasectomized (with documented azoospermia), to use a highly effective method of contraception consistently and correctly starting from 1 month prior to Screening until at least 45 days after the last dose of IP.
8. Participants assigned male at birth who are sexually active with a female partner of childbearing potential are eligible to participate if they agree to use a condom, and have either been vasectomized (with documented azoospermia) or agree to have their partner use a highly effective method of contraception from Day 1 until at least 105 days after the last dose of IP.
9. Participants must refrain from donating eggs (ova, oocytes) from Day 1 until at least 45 days or sperm from Day 1 until at least 105 days after receiving the last dose of the IP.
10. Participants, who, in the opinion of the Investigator, can and will comply with the requirements and restrictions, including lifestyle restrictions listed in the Protocol.
11. Able to swallow an oral solid-dosage form of medication.
12. For Part 3 (Food-Effect study) only, able to consume a standardized high-fat meal.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. History or current evidence of a clinically significant or uncontrolled underlying condition, including but not limited to cardiovascular, hepatic, renal, hematological, infectious, autoimmune, neurological, psychiatric, endocrine, gastrointestinal, reproductive, pulmonary, or ocular. Clinically significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation or which could affect the endpoint analysis if the disease/condition worsened during the study. EXCEPTION: Fully resolved childhood asthma is not exclusionary.
2. History of or current invasive malignancy including hematological malignancies. Participants with a history of basal cell or squamous cell carcinoma or other carcinomas in situ that has been treated with no evidence of recurrence within 1 year prior to Screening will be allowed for inclusion, as judged by the Investigator.
3. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
4. Any current active infections, including localized infections, or any recent history of active infections, cough, or fever within 1 week prior to IP administration (including severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), or any history of recurrent or chronic infections.
5. Known history of significant multiple and/or severe allergies (e.g., food, drug, or latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or nonprescription drugs or food. EXCEPTION: Untreated, asymptomatic, seasonal allergies are not exclusionary.
6. Family history of sudden death or of congenital prolongation of the QT interval corrected for heart rate (QTc) or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.
7. Known or suspected hypersensitivity to any component of the finished dosage form of PROT-001.
8. Tested positive for hepatitis B surface antigen, anti-hepatitis C virus antibodies, and anti-human immunodeficiency virus 1 and 2 antibodies at Screening.
9. In the 12-lead ECG assessment at Screening or on days of admission to the study site (Day -1 and Day 14, as appropriate), QTcF >450 msec. NOTE: One repeat screen is allowed at the discretion of the Investigator.
10. Has absolute neutrophil count (ANC) <2 × 109/L or aspartate transaminase (AST) and alanine transaminase (ALT) >1.5 × ULN, or INR >1.2 at Screening or on days of admission to the study site (Day -1 and Day 14, as appropriate).
11. Has positive urine drug (excluding positive for cotinine) or alcohol breath test results at Screening or on days of admission to the study site (Day -1 and Day 14, as appropriate).
12. Use of more than 10 tobacco nicotine-containing products (e.g., 10 cigarettes) per week within 3 months prior to the first IP administration and should agree to follow the restrictions related to tobacco/nicotine-containing consumption during the study, as outlined in the Protocol.
13. Any history of alcohol abuse, with an average intake exceeding 21 drinks per week for men, 14 drinks per week for women, or >4 drinks in 1 sitting several times a week (1 drink is equivalent to 12 g alcohol [i.e., 150 mL of wine, 360 mL of beer, or 45 mL of 80-proof distilled spirits]) or drug addiction (including soft drugs like cannabis products).
14. Use of any prescription or nonprescription medications, including over-the-counter (OTC) medications, vitamins, multivitamins, recreational drugs, dietary supplements, and herbal remedies such as St. John's Wort extract, or drugs considered likely to interfere with the safe conduct of the study within 7 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of the IP, or their planned use during the study period. EXCEPTIONS: After randomization, ibuprofen (=1.2 g in 24 hours) and/or paracetamol (=4 g in 24 hours but =1 g in 4 hours) may be administered at the discretion of the Investigator or delegate. Thyroid hormone replacement medication may be permitted if the participant has been on same stable dose for the last 3 months prior to the first dose of IP. Hormone replacement therapy and hormonal contraceptives will also be allowed.
15. Received an investigational drug within 30 days or 5 half-lives (whichever is greater) prior to the first dose of IP.
16. Has received any live vaccines (bacterial or viral) within 30 days prior to the first dose of IP or intend to receive a live vaccine during the study period.

EXCEPTIONS: Vaccines allowed by the protocol include inactivated flu and COVID-19 vaccines in all participants. The recommended time intervals for administration of these vaccines are at least 7 days before the first dose of IP or 7 days after the last dose of IP.
17. Plans to donate or has donated =350 mL of blood (including blood products) within 28 days prior to the first dose of IP.
18. Plans to donate or has donated plasma within 7 days prior to the first dose of IP.
19. Female participant who is pregnant, breastfeeding, or plans to become pregnant or donate ova for in vitro fertilization during the study period and for 45 days following the last dose of IP or male participant who plans to donate sperm for in vitro fertilization during the study period and for 105 days following the last dose of IP.
20. The participant is considered to be vulnerable (e.g., cognitively impaired, or a person kept in detention).
21. The participant is an employee of the study site or has a family member or household member involved with the conduct of this study.
22. Any reason that in the opinion of the Investigator would lead to the inability of the participant to comply with the protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/06/2025
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2026
Actual
Sample size
Target
102
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Nucleus Network Pty Ltd - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Protego Biopharma Pty Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Dr Ofer Gonen
Address 0 0
Country 0 0
Phone 0 0
1800 243 733
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06981299